Today's story
Roche beats sales forecasts, reaffirms outlook
Roche Q3 sales reached 16.13 billion Swiss francs, beating the roughly 15.8 billion franc analyst estimate, and the company reaffirmed its 2026 outlook.
Business · 8 sources · Oct 22, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About emicizumab
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai. Emicizumab is a bispecific factor IXa- and factor X-directed antibody.
Everything about emicizumab →